Clinical Trials Logo

CS1+ or BCMA+ Multiple Myeloma clinical trials

View clinical trials related to CS1+ or BCMA+ Multiple Myeloma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04662099 Recruiting - Clinical trials for CS1+ or BCMA+ Multiple Myeloma

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

Start date: March 25, 2020
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of the bispecific CAR T cells targeting CS1 and BCMA in patients with relapsed or refractory multiple myeloma.